The ASSURE study: HIV ‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir-Reference-Cited by-同舟云学术

The ASSURE study: HIV ‐1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir

Published:2015-07-14 Issue:2 Volume:17 Page:106-117
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Wohl DA¹,Bhatti L²,Small CB³,Edelstein H⁴,Zhao HH⁵,Margolis DA⁵,DeJesus E⁶,Weinberg WG⁷,Ross LL⁸,Shaefer MS⁸

Affiliation:

1. AIDS Clinical Trials Unit University of North Carolina Chapel Hill NC USA

2. AIDS Healthcare Foundation Beverly Hills CA USA

3. New York Medical College Valhalla NY USA

4. Alameda County Medical Center Oakland CA USA

5. GlaxoSmithKline, Research Triangle Park Research Triangle Park NC USA

6. Orlando Immunology Center Orlando FL USA

7. Kaiser Foundation Health Plan of Georgia, Inc. Atlanta GA USA

8. ViiV Healthcare, Research Triangle Park NC USA

Funder

ViiV Healthcare

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.12281

Reference40 articles.

1. Antiretroviral Treatment of Adult HIV Infection

2. Simplified Maintenance Therapy With Abacavir/Lamivudine and Atazanavir After Discontinuation of Ritonavir

3. Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

4. Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

5. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bone Quality in Relation to HIV and Antiretroviral Drugs;Current HIV/AIDS Reports;2022-06-20

2. Bone and the microbiome;Marcus and Feldman's Osteoporosis;2021

3. Bone turnover markers in children living with HIV remaining on ritonavir-boosted lopinavir or switching to efavirenz;Bone;2020-09

4. Do interventions to improve adherence to antiretroviral therapy recognise diversity? A systematic review;AIDS Care;2020-08-27

5. Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression;Journal of Microbiology, Immunology and Infection;2019-12